1. Oncologic outcomes after minimally invasive segmentectomy or lobectomy in patients with hypermetabolic clinical stage IA1-2 non–small cell lung cancerCentral MessagePerspective
- Author
-
Alessandro Brunelli, MD, Joshil Lodhia, MD, Richard Milton, MD, Marco Nardini, MD, Kostas Papagiannopoulos, MD, Peter Tcherveniakov, MD, Demetrios Stefanou, MD, Elaine Teh, MD, and Nilanjan Chaudhuri, MD
- Subjects
segmentectomy ,lobectomy ,non–small cell lung cancer ,positron emission tomography ,event-free survival ,cancer-specific survival ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Surgery ,RD1-811 - Abstract
Objective: To evaluate the oncologic outcome of patients with hypermetabolic tumors resected by segmentectomy or lobectomy. Methods: This was a retrospective analysis of all consecutive patients with peripheral clinical stage IA1-2 non–small cell lung cancer (January 2017-June 2023) who underwent resection by segmentectomy or lobectomy in a single center. A hypermetabolic tumor was defined as a tumor with a positron emission tomography (PET) maximum standardized uptake value >2.5. Propensity score case-matching analysis was used to generate 2 balanced groups of patients with hypermetabolic tumors operated by segmentectomy or lobectomy. Four-year overall survival (OS), event-free survival (EFS), and cancer-specific survival were compared between the matched groups. Results: A total of 164 segmentectomies and 234 lobectomies were analyzed. There were 91 (55%) hypermetabolic tumors in the segmentectomy group versus 178 in the lobectomy group (76%), P
- Published
- 2024
- Full Text
- View/download PDF